meta|Evidence - COVID-19
click on circles to display study description...
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) (n=418) vs. placebo (n=419)
randomized controlled trial risk of bias NA
BRII-196/BRII-198
placebo
COVID 19 outpatients
results from interim analysis; divulged in a press release dated on October and December, 2021 *Warning! The spread of new Sars-Cov2 variants is constantly evolving, this study was performed in a different viral context than today, its results should be interpreted accordingly.*
bamlanivimab monotherapy (n=101) vs. placebo (n=156)
randomized controlled trial some concerns about risk of bias
Bamlanivimab (LY-CoV555) 700 mg
placebo
5 arms: placebo, bamlanivimab 700 mg, 2800 mg, and 7000 mg and 2800 mg of bamlanivimab and 2800 mg of etesevimab
COVID 19 outpatients
double-blind
Phase 2: exploratory trial, originally designed as a safety and biomarker study. Inconclusive for the primary endpoint.
As of April 2021, regulatory authorities recommend that bamlanivumab no longer be used because of the potential risk of treatment failure due to the circulation of resistant variants of SARS-CoV-2.
bamlanivimab/etesevimab (n=-9) vs. casirivimab/imdevimab (Ronapreve) (n=-9)
randomized controlled trial high risk of bias
bamlanivimab-etesevimab
casirivimab-imdevimab
COVID 19 outpatients
open- label
Pennsylvania, USA
All pharmacies supplying all infusion sites had equal opportunity to order any available mAb from a central supply facility. All mAb were ordered by prescribers as a generic referral order
bamlanivimab/etesevimab (n=158) vs. placebo (n=153)
randomized controlled trial risk of bias NA
bamlanivimab 700 mg and etesevimab 1,400 mg
placebo
3 arms : 700 mg bamlanivimab and 1,400 mg etesevimab, 2,800 mg bamlanivimab and 2,800 mg of etesevimab, and placebo
COVID 19 outpatients
double-blind
phase 2, ongoing, interim analysis (without precision about prespecification and type 1 risk control)
UNPUBLISHED preliminary data, from FDA EUA fact sheet. October, 2021 EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly. Janvier, 2022: FDA limit the use of bamlanivimab and etesevimab to infection due to susceptible variants (ie not omicron).
bamlanivimab/etesevimab (n=112) vs. placebo (n=156)
randomized controlled trial some concerns about risk of bias
bamlanivimab 2800 mg and etesevimab 2800 mg
placebo
5 arms: placebo, bamlanivimab 700 mg, 2800 mg, and 7000 mg and 2800 mg of bamlanivimab and 2800 mg of etesevimab
COVID 19 outpatients
double-blind
Phase 2. Exploratory trial, originally designed as a safety and biomarker study.
October, 2021 EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly. Janvier, 2022: FDA limit the use of bamlanivimab and etesevimab to infection due to susceptible variants (ie not omicron).
bamlanivimab/etesevimab (n=518) vs. placebo (n=517)
randomized controlled trial some concerns about risk of bias
bamlanivimab 2,800 mg plus etesevimab 2,800 mg
single intravenous (IV) infusion within 3 days of having a positive result on a SARS-CoV-2 virologic test
placebo
COVID 19 outpatients
Participants were excluded if they had a saturation of oxygen (SpO2) ≤93% on room air, respiratory rate ≥30 breaths/min, or heart rate ≥125 bpm
double-blind
October, 2021 EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly. Janvier, 2022: FDA limit the use of bamlanivimab and etesevimab to infection due to susceptible variants (ie not omicron).
Bebtelovimab (LY-CoV1404) (n=-9) vs. placebo (n=-9)
randomized controlled trial risk of bias NA
single-dose bebtelovimab
placebo
COVID 19 outpatients
double-blind
phase 1/2
casirivimab/imdevimab (Ronapreve) (n=156) vs. placebo (n=158)
randomized controlled trial some concerns about risk of bias
Casirivimab 600 mg and imdevimab 600 mg
Single 1200 mg dose.
Placebo
Placebo at day 1 via subcutaneous injection.
COVID 19 outpatients
Double-blind.
112 sites in the US, Romania and Moldova.
The trial consists of a 1-day screening/baseline period, a 28-day efficacy assessment period (EAP), and a 7-month follow-up period.
*Warning! The spread of new Sars-Cov2 variants is constantly evolving, this study was performed in a different viral context than today, its results should be interpreted accordingly.*
casirivimab/imdevimab (Ronapreve) (n=838) vs. placebo (n=840)
randomized controlled trial some concerns about risk of bias
REGEN-CO 1200mg (casirivimab and imdevimab) IV
Placebo
3 arms: placebo, REGEN-COV 2400mg (1200mg each antibody) and REGEN-COV 1200mg (600mg each antibody). (8,000 mg data were converted to a descriptive analysis)
COVID 19 outpatients
Patients ≥18 years of age and non-hospitalized, with a confirmed local SARS-CoV-2-positive diagnostic test result ≤72 hours and onset of any Covid-19 symptom, as determined by the investigator, ≤7 days before randomization, maintain O2 saturation ≥93% breathing room air, not have prior or current use of putative COVID-19 treatments (e.g. convalescent plasma, systemic corticosteroids or remdesivir) and not have been previously or currently hospitalized for treatment of COVID-19.
Double-blind.
Analysis in modified full analysis set (subjects with positive RT-qPCR test at baseline).The primary and two key secondary endpoints were tested hierarchically. The key secondary clinical endpoints were (1) the proportion of patients with ≥1 Covid-19-related hospitalization or all-cause death from day 4 through day 29 and (2) the time to Covid-19 symptoms resolution (19 of the 23 recorded symptoms).
*Warning! The spread of new Sars-Cov2 variants is constantly evolving, this study was performed in a different viral context than today, its results should be interpreted accordingly.*
cilgavimab and tixagevimab (Evusheld) (n=452) vs. placebo (n=451)
randomized controlled trial risk of bias NA
cilagavimab/tixagévimab
a single 600mg IM
placebo
COVID 19 outpatients
double blind
96 sites in Brazil, Czech Republic, Germany, Hungary, Italy, Japan, Mexico, Poland, Russian Federati
*Warning! The spread of new Sars-Cov2 variants is constantly evolving, this study was performed in a different viral context than today, its results should be interpreted accordingly.* from press AZ release https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-phiii-trial-positive-in-covid-outpatients.html
regdanvimab (Regkirona- CT-P59-Celltrion) (n=656) vs. placebo (n=659)
randomized controlled trial risk of bias NA
regdanvimab 40 mg/kg
Single infusion (drip) into a vein within 7 days of the start of COVID-19 symptoms of regdanvimab at dose of 40 mg/kg over 60 minutes.
placebo
Single infusion of placebo over 60 minutes.
COVID 19 outpatients
Adult patients with at least one or more symptoms of COVID-19 for ≤7 days, oxygen saturation >94% on room air, not requiring supplemental oxygen therapy. 66.9% of patients were at increased risk of progressing to severe COVID-19 and/or hospitalisation (defined as having at least one of the following risk factors for severe COVID-19: age >50 years; BMI >30 kg/m2; cardiovascular disease, including hypertension; chronic lung disease, including asthma; type 1 or type 2 diabetes mellitus; chronic kidney disease, including those on dialysis; chronic liver disease; and immunosuppressed, based on investigator’s assessment). Treatment was initiated after obtaining a positive SARS-CoV-2 viral infection determination.
double-blind
60 study centres across 14 countries, Hungary, Ireland, Italy, Mexico, North Macedonia, Peru, Poland
If the primary endpoint is statistically significant, the key secondary endpoints will be tested using the fixed sequence procedure in order to preserve the Type I error
preliminary unpublished results extracted from the EMA review document. *Warning! The spread of new Sars-Cov2 variants is constantly evolving, this study was performed in a different viral context than today, its results should be interpreted accordingly.*
regdanvimab (Regkirona- CT-P59-Celltrion) (n=226) vs. placebo (n=111)
randomized controlled trial risk of bias NA
regdanvimab 40 mg/kg or 80 mg/kg
single infusion
placebo
3 arms: single infusion of regdanvimab at doses of 40 mg/kg, 80 mg/kg, or placebo
COVID 19 outpatients
double-blind
23 study centres across 4 countries, Republic of Korea, Romania, Spain and United States
The study was explorative and did not have a type-1 error controlled primary endpoint
preliminary unpublished results extracted from the EMA review document. *Warning! The spread of new Sars-Cov2 variants is constantly evolving, this study was performed in a different viral context than today, its results should be interpreted accordingly.*
sotrovimab (Xevudy; VIR-7831) (n=528) vs. placebo (n=529)
randomized controlled trial low risk of bias
Sotrovimab (VIR-7831, GSK4182136) as monotherapy
Intravenous infusion of sotrovimab 500 mg over 1 hour on day 1.
Placebo
Equal volume of saline placebo over 1 hour on day 1.
Patients were observed for approximately 2 hours after infusion.
COVID 19 outpatients
18 years of age and older with at least one of the following comorbidities: diabetes, obesity (BMI >30), chronic kidney disease, congestive heart failure, chronic obstructive pulmonary disease, or moderate to severe asthma, or were 55 years of age and older regardless of comorbidities. Participants must have a positive SARS-CoV-2 test result and oxygen saturation ≥94% on room air and have COVID-19 symptoms and be less than or equal to 5 days from onset of symptoms
Double-blind.
57 centers in 5 countries: US, Brazil, Spain, Canada, Peru.
*Warning! The spread of new Sars-Cov2 variants is constantly evolving, this study was performed in a different viral context than today, its results should be interpreted accordingly.* data reported in FDA emergency use authorization (EUA), results from interim analysis.
powered by vis.js Network